Correlation Between ImmuCell and Lineage Cell

Can any of the company-specific risk be diversified away by investing in both ImmuCell and Lineage Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ImmuCell and Lineage Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ImmuCell and Lineage Cell Therapeutics, you can compare the effects of market volatilities on ImmuCell and Lineage Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ImmuCell with a short position of Lineage Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of ImmuCell and Lineage Cell.

Diversification Opportunities for ImmuCell and Lineage Cell

-0.67

Correlation Coefficient

ImmuCell  Lineage Cell

Excellent diversification

The 3 months correlation between ImmuCell and Lineage is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding ImmuCell and Lineage Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lineage Cell Therapeutics and ImmuCell is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ImmuCell are associated (or correlated) with Lineage Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lineage Cell Therapeutics has no effect on the direction of ImmuCell i.e., ImmuCell and Lineage Cell go up and down completely randomly.

Pair Corralation between ImmuCell and Lineage Cell

Given the investment horizon of 90 days ImmuCell is expected to generate 0.54 times more return on investment than Lineage Cell. However, ImmuCell is 1.87 times less risky than Lineage Cell. It trades about 0.14 of its potential returns per unit of risk. Lineage Cell Therapeutics is currently generating about -0.12 per unit of risk. If you would invest  358.00  in ImmuCell on September 14, 2024 and sell it today you would earn a total of  106.00  from holding ImmuCell or generate 29.61% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

ImmuCell  vs.  Lineage Cell Therapeutics

ImmuCell

Risk-Adjusted Performance

11 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in ImmuCell are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile fundamental indicators, ImmuCell exhibited solid returns over the last few months and may actually be approaching a breakup point.

Lineage Cell Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lineage Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with ImmuCell and Lineage Cell

The main advantage of trading using opposite ImmuCell and Lineage Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ImmuCell position performs unexpectedly, Lineage Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will offset losses from the drop in Lineage Cell's long position.

The idea behind ImmuCell and Lineage Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.